Is Zentalis Pharmaceuticals Stock a Good Investment?
Zentalis Pharmaceuticals Investment Advice | ZNTL |
- Examine Zentalis Pharmaceuticals' financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research Zentalis Pharmaceuticals' leadership team and their track record. Good management can help Zentalis Pharmaceuticals navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Pharmaceutical Products space and any emerging trends that could impact Zentalis Pharmaceuticals' business and its evolving consumer preferences.
- Compare Zentalis Pharmaceuticals' performance and market position to its competitors. Analyze how Zentalis Pharmaceuticals is positioned in terms of product offerings, innovation, and market share.
- Check if Zentalis Pharmaceuticals pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about Zentalis Pharmaceuticals' stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in Zentalis Pharmaceuticals Llc stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if Zentalis Pharmaceuticals Llc is a good investment.
Sell | Buy |
Strong Sell
Market Performance | Very Weak | Details | |
Volatility | Dangerous | Details | |
Hype Condition | Stale | Details | |
Current Valuation | Overvalued | Details | |
Odds Of Distress | Very High | Details | |
Economic Sensitivity | Responds to the market | Details | |
Investor Sentiment | Alarmed | Details | |
Analyst Consensus | Not Available | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unavailable | Details |
Examine Zentalis Pharmaceuticals Stock
Researching Zentalis Pharmaceuticals' stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). About 13.0% of the company outstanding shares are owned by insiders. The company has Price to Book (P/B) ratio of 0.33. Historically many companies with similar price-to-book (P/B) ratio do better than the market in the long run. Zentalis Pharmaceuticals recorded a loss per share of 2.5. The entity had not issued any dividends in recent years.
To determine if Zentalis Pharmaceuticals is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Zentalis Pharmaceuticals' research are outlined below:
Zentalis Pharmaceuticals generated a negative expected return over the last 90 days | |
Zentalis Pharmaceuticals has high historical volatility and very poor performance | |
Zentalis Pharmaceuticals may become a speculative penny stock | |
Zentalis Pharmaceuticals has a very high chance of going through financial distress in the upcoming years | |
Net Loss for the year was (292.19 M) with profit before overhead, payroll, taxes, and interest of 40.56 M. | |
Zentalis Pharmaceuticals Llc currently holds about 455.22 M in cash with (207.82 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 7.99, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
Over 98.0% of the company outstanding shares are owned by institutional investors |
Zentalis Pharmaceuticals uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Zentalis Pharmaceuticals Llc. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Zentalis Pharmaceuticals' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
6th of March 2024 Upcoming Quarterly Report | View | |
8th of May 2024 Next Financial Report | View | |
31st of December 2023 Next Fiscal Quarter End | View | |
6th of March 2024 Next Fiscal Year End | View | |
30th of September 2023 Last Quarter Report | View | |
31st of December 2022 Last Financial Announcement | View |
Zentalis Pharmaceuticals' market capitalization trends
The company currently falls under 'Small-Cap' category with a current market capitalization of 118.3 M.Basic technical analysis of Zentalis Stock
As of the 31st of January, Zentalis Pharmaceuticals maintains the Standard Deviation of 6.16, market risk adjusted performance of (0.81), and Mean Deviation of 4.57. Relative to fundamental indicators, the technical analysis model lets you check existing technical drivers of Zentalis Pharmaceuticals Llc, as well as the relationship between them. Please check out Zentalis Pharmaceuticals risk adjusted performance, information ratio, as well as the relationship between the Information Ratio and kurtosis to decide if Zentalis Pharmaceuticals is priced fairly, providing market reflects its latest price of 1.66 per share. Please also validate Zentalis Pharmaceuticals jensen alpha, which is currently at (1.28) to confirm the company can sustain itself at a future point.Zentalis Pharmaceuticals' insider trading activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Zentalis Pharmaceuticals insiders, such as employees or executives, is commonly permitted as long as it does not rely on Zentalis Pharmaceuticals' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Zentalis Pharmaceuticals insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Roth Iris over three months ago Acquisition by Roth Iris of 297500 shares of Zentalis Pharmaceuticals at 18.87 subject to Rule 16b-3 | ||
Vincent Vultaggio over three months ago Disposition of 1603 shares by Vincent Vultaggio of Zentalis Pharmaceuticals at 3.18 subject to Rule 16b-3 | ||
Hausman Diana over three months ago Insider Trading | ||
Johnson David Michael over six months ago Acquisition by Johnson David Michael of 48429 shares of Zentalis Pharmaceuticals subject to Rule 16b-3 | ||
Gallagher Cam over six months ago Disposition of 9597 shares by Gallagher Cam of Zentalis Pharmaceuticals at 11.98 subject to Rule 16b-3 | ||
Walker Luke Nathaniel over six months ago Insider Trading | ||
Vultaggio Vincent over six months ago Disposition of 25000 shares by Vultaggio Vincent of Zentalis PharmaceuticalsL at 11.69 subject to Rule 16b-3 |
Zentalis Pharmaceuticals' Outstanding Corporate Bonds
Zentalis Pharmaceuticals issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Zentalis Pharmaceuticals uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Zentalis bonds can be classified according to their maturity, which is the date when Zentalis Pharmaceuticals Llc has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
Dana 575 percent Corp BondUS235822AB96 | View | |
HSBC Holdings PLC Corp BondUS404280DR76 | View | |
MPLX LP 4125 Corp BondUS55336VAK61 | View |
Understand Zentalis Pharmaceuticals' technical and predictive indicators
Using predictive indicators to make investment decisions involves analyzing Zentalis Pharmaceuticals' various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.
Risk Adjusted Performance | (0.15) | |||
Market Risk Adjusted Performance | (0.81) | |||
Mean Deviation | 4.57 | |||
Coefficient Of Variation | (538.08) | |||
Standard Deviation | 6.16 | |||
Variance | 37.89 | |||
Information Ratio | (0.20) | |||
Jensen Alpha | (1.28) | |||
Total Risk Alpha | (1.82) | |||
Treynor Ratio | (0.82) | |||
Maximum Drawdown | 32.39 | |||
Value At Risk | (12.15) | |||
Potential Upside | 8.0 | |||
Skewness | (0.85) | |||
Kurtosis | 1.25 |
Risk Adjusted Performance | (0.15) | |||
Market Risk Adjusted Performance | (0.81) | |||
Mean Deviation | 4.57 | |||
Coefficient Of Variation | (538.08) | |||
Standard Deviation | 6.16 | |||
Variance | 37.89 | |||
Information Ratio | (0.20) | |||
Jensen Alpha | (1.28) | |||
Total Risk Alpha | (1.82) | |||
Treynor Ratio | (0.82) | |||
Maximum Drawdown | 32.39 | |||
Value At Risk | (12.15) | |||
Potential Upside | 8.0 | |||
Skewness | (0.85) | |||
Kurtosis | 1.25 |
Consider Zentalis Pharmaceuticals' intraday indicators
Zentalis Pharmaceuticals intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Zentalis Pharmaceuticals stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
Zentalis Pharmaceuticals time-series forecasting models is one of many Zentalis Pharmaceuticals' stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Zentalis Pharmaceuticals' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.
Zentalis Stock media impact
Far too much social signal, news, headlines, and media speculation about Zentalis Pharmaceuticals that are available to investors today. That information is available publicly through Zentalis media outlets and privately through word of mouth or via Zentalis internal channels. However, regardless of the origin, that massive amount of Zentalis data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Zentalis Pharmaceuticals news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Zentalis Pharmaceuticals relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Zentalis Pharmaceuticals' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Zentalis Pharmaceuticals alpha.
Zentalis Pharmaceuticals Corporate Management
Vincent Vultaggio | VP Officer | Profile | |
Kevin Bunker | CoFounder Officer | Profile | |
Carrie MD | Chief Officer | Profile | |
Adrian MD | Executive Development | Profile | |
Mark Lackner | Chief Strategy | Profile | |
Ingmar MD | Chief Officer | Profile | |
Kimberly Freeman | Chief Officer | Profile |
Already Invested in Zentalis Pharmaceuticals Llc?
The danger of trading Zentalis Pharmaceuticals Llc is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Zentalis Pharmaceuticals is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Zentalis Pharmaceuticals. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Zentalis Pharmaceuticals is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
When determining whether Zentalis Pharmaceuticals is a strong investment it is important to analyze Zentalis Pharmaceuticals' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Zentalis Pharmaceuticals' future performance. For an informed investment choice regarding Zentalis Stock, refer to the following important reports: Check out Your Current Watchlist to better understand how to build diversified portfolios, which includes a position in Zentalis Pharmaceuticals Llc. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as various price indices. You can also try the Sign In To Macroaxis module to sign in to explore Macroaxis' wealth optimization platform and fintech modules.
Is Pharmaceutical Products space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Zentalis Pharmaceuticals. If investors know Zentalis will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Zentalis Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Zentalis Pharmaceuticals is measured differently than its book value, which is the value of Zentalis that is recorded on the company's balance sheet. Investors also form their own opinion of Zentalis Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Zentalis Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Zentalis Pharmaceuticals' market value can be influenced by many factors that don't directly affect Zentalis Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
In summary, please note that there is a difference between Zentalis Pharmaceuticals' value and its price, as these two are different measures arrived at by various means. Investors typically determine if Zentalis Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Zentalis Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.